The Glucagon‐like peptide‐1 receptor agonist, exendin‐4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome

Abstract

Glucagon‐like peptide‐1 (GLP‐1) is beneficial in relieving pain‐related symptoms of Irritable bowel syndrome (IBS), a prevalent, multi‐factorial functional bowel disorder characterized by diarrhea and/or constipation, abdominal bloating, and pain. Activation of myenteric neurons has been implicated in the inhibitory effects of GLP‐1 on gastrointestinal motility; however, the mechanisms of action underlying this are not clear.